Studies conducted at MTR were approved by various regulatory bodies such as
US FDA,
TPD-Canada,
EMEA,
ANSM-France,
ANVISA-Brazil,
Bfarm-German,
TGA-Australia,
MCC-South Africa,
Russia,
Belgium,
Philippines,
WHO, etc.
MTR has successfully exceeded the dual audit of Bfarm (German) and ANSM (France) in March 2013, Market Authorization has granted for audited molecule.
All three facilities {Selaiyur, Padi, Coimbatore) of MTR are registered with FDA for self identified , as per Generic Drug User Fee Amendments of 2012 (GDUFA) -FDA for fiscal year 2014.
MTR has successfully completed US-FDA audit in Dec 2012 with NIL 483.
MTR Chennai CBE facilities Were approved by ANVISA (Brazil).
MTR is shortlisted among 5 Best Contract Research Organization in the year 2012, by Scrip Intelligence Awards.
MTR has obtained reorganization from DSIR as RESEARCH CENTER in the month of July 2012.
Forthcoming
On 15 Feb 2014, MTR will successfully complete its 9th year of operation.
In 2014-MTR will provide extensive services in the field of Preclinical trial, Biosimilar, Stem cell.
MTR has applied for registration of its bioequivalence(BE) centre to Centre of New products, NPCB, ministry of health Malaysia.
US FDA,
TPD-Canada,
EMEA,
ANSM-France,
ANVISA-Brazil,
Bfarm-German,
TGA-Australia,
MCC-South Africa,
Russia,
Belgium,
Philippines,
WHO, etc.
MTR has successfully exceeded the dual audit of Bfarm (German) and ANSM (France) in March 2013, Market Authorization has granted for audited molecule.
All three facilities {Selaiyur, Padi, Coimbatore) of MTR are registered with FDA for self identified , as per Generic Drug User Fee Amendments of 2012 (GDUFA) -FDA for fiscal year 2014.
MTR has successfully completed US-FDA audit in Dec 2012 with NIL 483.
MTR Chennai CBE facilities Were approved by ANVISA (Brazil).
MTR is shortlisted among 5 Best Contract Research Organization in the year 2012, by Scrip Intelligence Awards.
MTR has obtained reorganization from DSIR as RESEARCH CENTER in the month of July 2012.
Forthcoming
On 15 Feb 2014, MTR will successfully complete its 9th year of operation.
In 2014-MTR will provide extensive services in the field of Preclinical trial, Biosimilar, Stem cell.
MTR has applied for registration of its bioequivalence(BE) centre to Centre of New products, NPCB, ministry of health Malaysia.
Welcome
Micro Therapeutic Research Labs Private Limited (MTR) is a quality driven, full service Contract Research Organization (CRO) that provides a broad range of clinical research services to global Pharmaceutical, biotechnology, nutraceutical and cosmetic industry.
Spread over four different locations which includes three sites at Chennai and one site at Coimbatore.
Regulatory Status and Accreditation